Plasmablastic Lymphoma clinical trials

Explore recruiting plasmablastic lymphoma clinical trials.

Recruiting plasmablastic lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Plasmablastic Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

France, Poland, Romania, Italy, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Plasmablastic Lymphoma trials by city

Plasmablastic Lymphoma clinical trials

Recruiting plasmablastic lymphoma studies right now

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Study of SGR-1505 in Mature B-Cell Neoplasms

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Also recruiting in Europe

An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial)

First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

Plasmablastic Lymphoma trials by city

Other conditions